Vivos Therapeutics (VVOS) Total Current Liabilities (2019 - 2026)
Vivos Therapeutics (VVOS) posted quarterly Total Current Liabilities of $17.9 million for Q1 2026, up 281.56% year-over-year from $4.7 million in Q1 2025, and down 0.77% quarter-over-quarter from $18.1 million in Q4 2025.
Vivos Therapeutics (VVOS) Total Current Liabilities (2019 - 2026) Analysis & Trends
Vivos Therapeutics (VVOS) has reported Total Current Liabilities for 8 consecutive years, with $17.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 281.56% year-over-year to $17.9 million; the TTM figure through Mar 2026 stood at $17.9 million (up 281.56% YoY), while the FY2025 annual figure was $18.1 million, up 263.12% from the prior year.
- Total Current Liabilities fell to $17.9 million in Q1 2026 per VVOS's latest filing, from $18.1 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $18.1 million in Q4 2025 and bottomed at $4.7 million in Q1 2025.
- Historically, Total Current Liabilities has averaged $8.0 million across 5 years, with a median of $6.8 million in 2022.
- Annual changes were most pronounced in 2025 — Total Current Liabilities tumbled 41.75% — and 2026, when it soared 281.56%.
- Vivos Therapeutics' Total Current Liabilities stood at $6.8 million in 2022, then grew by 6.99% to $7.3 million in 2023, then plunged by 31.71% to $5.0 million in 2024, then soared by 263.12% to $18.1 million in 2025, then declined by 0.77% to $17.9 million in 2026.
- Business Quant data shows VVOS's Total Current Liabilities at $17.9 million in Q1 2026, $18.1 million in Q4 2025, and $7.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | 17.81 Bn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 6.68 Bn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 11.66 Bn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 6.43 Bn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | 1.51 Bn |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | 2.36 Bn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | 8.30 Bn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | 8.63 Bn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | 1.28 Bn |
| 10 | Vivos Therapeutics | 5.18 Mn | 3.38 Mn | 2.95 Mn | 20.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.94 Mn |
| Dec 31, 2025 | 18.08 Mn |
| Sep 30, 2025 | 7.44 Mn |
| Jun 30, 2025 | 6.43 Mn |
| Mar 31, 2025 | 4.70 Mn |
| Dec 31, 2024 | 4.98 Mn |
| Sep 30, 2024 | 5.13 Mn |
| Jun 30, 2024 | 6.64 Mn |
| Mar 31, 2024 | 8.07 Mn |
| Dec 31, 2023 | 7.29 Mn |
| Sep 30, 2023 | 7.17 Mn |
| Jun 30, 2023 | 8.44 Mn |
| Mar 31, 2023 | 7.98 Mn |
| Dec 31, 2022 | 6.81 Mn |
| Sep 30, 2022 | 5.96 Mn |
| Jun 30, 2022 | 6.69 Mn |
| Mar 31, 2022 | 6.29 Mn |
| Dec 31, 2021 | 7.51 Mn |
| Sep 30, 2021 | 8.20 Mn |
| Jun 30, 2021 | 9.31 Mn |